There is a considerable difference of opinion between clinicians on opposite sides of the Atlantic about the role of antacid therapy in peptic ulcer. As a result of Doll' s work1 most clinicians in the United Kingdom have considered antacids to be of symptomatic benefit only, but without effect on the natural history of disease. In the United States, however, antacids have remained the basic medical treatment for peptic ulcer and large quantities are prescribed in intensive regimens with the belief that they accelerate ulcer healing. Such a difference of opinion usually means that the treatment in question is without any dramatic effect and objective assessment is therefore different. It is in this field that randomised, controlled trials are most helpful, indeed vital2. Carbenoxolone3 and recently the H 2-receptor antagonists4'5 have been tested in this way and found to be effective in healing peptic ulcer. We feel a review of similar work on antacids is appropriate.
The use of antacids is based on the premise that gastric acid plays some part in the causation of peptic ulcer and also on the observation that symptoms are often relieved by antacid preparations. Schwarz's dictum, 'no acid-no ulcer', is still valid, though the pattern of acid secretion is different in gastric and duodenal ulcer. Hypersecretion of acid is probably a more important factor in duodenal ulcer, though several aspects of the pathophysiology remain controversial6. Most patients with an ulcer in the body or fundus of the stomach have normal or low rates of acid secretion and changes in mucosal resistance are probably more important7'8. Reflux of bile into the stomach probably causes gastric mucosal damage which may play a part in the pathogenesis of gastric ulcer9. Antacids may not only neutralise gastric contents but in the case of aluminium hydroxide also bind bile acids'0.
Peptic activity is difficult to separate from acid secretion and its role is similarly ill-defined. A rise in gastric pH to 5 will inactivate pepsin; calcium carbonate has also been shown to produce a marked reduction in pepsin activity, while aluminium hydroxide, in spite of binding to pepsin, has little effect".
The total cost of antacids in the United Kingdom during 1976 was about 20 million pounds, a figure which includes both Health Service prescriptions and over-the-counter sales. The so-called semi-ethical preparations are available on prescription or from a pharmacist but are not advertised to the general public. The cost to the Health Service of these preparations is about 12 million pounds per annum-7 million for plain antacids, 4 million for silicone-containing antacids, and 1 million pounds for antacids combined with antispasmodics or local anaesthetics. While the cost to the Health Service has grown considerably in recent years because of inflation, the number of prescriptions has remained constant at 91 million per annum. Liquid preparations are prescribed more often than tablets and siliconecontaining antacids are increasingly prescribed in place of plain preparations.
There is comparatively little precise information available about over-thecounter sales of antacids, although the total market value of these products is about 81 million pounds per annum and these sales have tended to decline in recent years.
Most prescribed antacids contain a mixture of aluminium and magnesium salts, which minimises bowel disturbance. Precise methods of preparation and presentation are important because they influence the physicochemical properties and the therapeutic effect of antacids. For example, Littman'2 Fordtran and Collyns22 investigated the effect of two antacid regimens on gastric acidity in patients with duodenal ulcer eating a normal diet and found that 4 g calcium carbonate given one hour after a meal lowered gastric acidity for at least three hours compared with controls. The duration of action was only 20 to 40 minutes when the same dose of calcium carbonate was given on an empty stomach. Anticholinergics given before food did not influence the effect of antacid but larger doses of antacid prolonged the effect after food but not while fasting. Aluminium-magnesium hydroxide gave similar results but was less effective than calcium carbonate. A recent paper from the Mayo Clinic23 compared the delivery of acid to the duodenum after food in patients with duodenal ulcer given the H2-receptor antagonist cimetidine, or aluminium-magnesium-hydroxide. It was found that 400 mg cimetidine with a meal decreased the four-hour delivery into the duodenum of titratable acid and hydrogen ion by 63 % and 86% respectively (p < 0-01 versus control). The aluminium-magnesium-hydroxide regime (30 ml one hour and three hours after meals) lowered titratable acid and hydrogen ion concentration by 47 % and 74% respectively (p < 0-01 versus control). The decrease in acid delivered to the duodenum was comparable in degree, though the results with antacid showed greater fluctuation than after cimetidine.
Another phenomenon of importance is rebound hyperacidity after antacid therapy24 which occurs with calcium carbonate specifically25 and not with other antacid preparations. This is due to the direct effect of calcium on gastrin release and gastric acid secretion26' 27'28 .
The evidence currently available shows that antacids lower gastroduodenal acidity for considerable periods when given after food, although the quantities used were large compared with British practice. Do antacids accelerate healing in peptic ulcer? Doll and others29 examined the rate at which gastric ulcer healed in a group of inpatients who for four weeks were given a continuous intragastric milk drip alkalinised with sodium bicarbonate. There was no effect on the rate of healing compared with the control group. However, this regimen was similar to the one developed by Winkelstein et al.30 and was subsequently shown to produce only a modest reduction in gastric acid3l. Doll's control group also received antacids for relief of symptoms32. One cannot obtain from this study an answer regarding the efficacy of antacids in healing gastric ulcer; the study shows that a continuous intragastric milk drip together with prolonged but modest reduction in gastric acidity offers no further benefit to that obtained from bed-rest and symptomatic antacid therapy33.
Hollander and Harlan34 in a double-blind controlled trial examined the effect of antacids on the rate of healing in outpatients with peptic ulcer. The antacid regimen was two-hourly calcium carbonate (420 mg) and proved more effective than placebo in healing gastric ulcer (p = 0-04) but showed no benefit in duodenal ulcer. In a similar trial35 hospitalised patients with gastric ulcer were given a liquid antacid containing aluminium-magnesiumhydroxide, 60 ml every two hours, and endoscopy was used to assess healing. There was no benefit from this regimen compared with placebo. The conflicting results from these studies suggest that antacids do not have a marked effect on healing rate in gastric ulcer. The greater potency of calcium carbonate both as an antacid and anti-pepsin compared with aluminiummagnesium-hydroxide may partly explain the results. Admission to hospital is known to accelerate healing in gastric ulcer and if the benefit obtained from antacid therapy is slight it could easily be lost during an inpatient trial. Thus, carbenoxolone is effective in healing gastric ulcer in outpatients3 but not in inpatients36.
A major problem in the assessment of healing in duodenal ulcer has been There were no significant differences between antacid and placebo in the time of onset, degree or duration of pain relief. This surprising result led the authors to suggest that factors other than reduction of gastric acidity may be important in acute relief of spontaneous duodenal ulcer pain. Both the antacid and the placebo used in this work contained peppermint oil and the carminative effect of the latter may partly account for the failure to show a difference between the preparations.
However, Littman et al.44 reported studies with alumimum hydroxide gel in acute relief of pain in peptic ulcer. The analgesic effect of a single dose of antacid versus placebo was tested in two ways-in spontaneous ulcer pain and in pain provoked by instilling acid into the stomach. The trials which were randomised and double-blind were conducted at two hospitals. Patients reported spontaneous ulcer pain to a nurse who then gave either active or placebo gel. The result was recorded 20 minutes later and complete relief of pain was the only index of effectiveness. When pain was provoked by instillation of acid the preparation which contained either antacid or placebo was also instilled via the nasogastric tube and effectiveness was taken as complete relief of pain at 10 minutes. In one of the hospitals complete relief of pain was obtained with 15 ml aluminium-hydroxide-gel in 79% and with placebo in 45 % (p < 005); 44 spontaneous episodes of pain were used in the assessment. In the other hospital, doses of 15 ml and 30 ml were tried but 38 identical trials revealed no significant difference between aluminium hydroxide and placebo. At neither hospital was there any significant advantage for aluminium hydroxide gel over placebo in relief of pain provoked by acid instillation.
The question of long-term relief of symptoms in peptic ulcer by antacids is also difficult to answer with any confidence. Relief of symptoms and healing need not go hand in hand45646'47. A surprising feature of the Dallas study37 was that, although the intensive antacid regime accelerated healing in duodenal ulcer, no benefit on symptoms was demonstrated compared with controls.
Hollander and Harlan34 found calcium carbonate more effective than placebo in relieving symptoms of gastric ulcer in outpatients. Butler and Gersh35, however,  55'56 Reduction in gastric acidity may also increase susceptibility to intestinal pathogens57. This old observation has recently been reviewed58 and, in a report given of people who drank Brucella-infected goat's milk, only the two patients who were currently taking aluminium magnesium antacid developed brucellosis.
Palatability becomes an important factor when large dose regimens are used, particularly in patients who may already be nauseated. In a recent study20 commonly prescribed antacids were compared for their palatability and acid neutralising capacity. Sixty normal subjects took part in the study and were divided into groups of 12. Each group assessed four antacids over four days and compared them with a standard and listed their preference. Although most preparations were palatable, some were quite unacceptable.
Summary
Antacids can reduce gastroduodenal acidity for long periods if taken in substantial quantities after food. Their healing effect on gastric ulcer is minimal, if present at all, and easily overwhelmed by the benefit obtained from admission to hospital. Intensive antacid therapy appears effective in healing duodenal ulcer and preventing haemorrhage from stress ulcer, and is comparable in these respects with cimetidine but with a higher incidence of side-effects. Clinical impression strongly suggests that antacids relieve pain in peptic ulcer but objective confirmation is lacking.
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